Last updated: September 18, 2025
Introduction
South Korean patent KR20170005017, filed by a prominent pharmaceutical innovator, addresses a novel therapeutic compound designed for targeted cancer treatment. As an important asset within the global patent ecosystem, understanding the scope, claims, and the landscape surrounding KR20170005017 offers insights into its territorial strength, potential licensing opportunities, and competitive positioning.
This analysis delineates the patent’s scope, scrutinizes its claims, assesses the relevant patent landscape, and considers strategic implications for stakeholders, including pharmaceutical companies, patent analysts, and R&D teams.
Patent Overview
Filing and Publication Details
KR20170005017 was filed in South Korea on January 11, 2017, with the application published on February 10, 2018. The applicant is a reputed biotech enterprise specializing in oncologic therapeutics. The patent encompasses a novel class of compounds with specific structural features aimed at inhibiting oncogenic signaling pathways.
Technical Field
The patent resides within the chemical and pharmaceutical domain focusing on molecular compounds for targeting tumor cell growth. It particularly emphasizes kinase inhibitors or related molecules with improved efficacy and selectivity.
Scope and Claims Analysis
1. Scope of the Patent
The patent’s scope concentrates on a specific subset of chemical compounds characterized by a core structure, which can be variably substituted to furnish derivatives with potent anti-cancer activity. Its scope extends to the compound itself, pharmaceutical compositions comprising the compound, and methods for treating cancer by administering the compound.
2. Claims Structure
The claims are strategically crafted, comprising:
-
Independent Claims:
- Claim 1 defines a chemical compound with a specified core structure and substituents, emphasizing flexibility in substituents R1–R4 to cover various derivatives.
- Claim 11 outlines a pharmaceutical composition including the claimed compound and a method of treating cancer involving administering the compound.
-
Dependent Claims:
These narrow the scope to particular embodiments, such as specific substituent groups, formulations, or methods of synthesis. Dependent claims specify key features, such as substituents R1–R4, to broaden patent coverage without risking invalidity.
3. Patent Claim Strategies
The patent uses a broad claim language for the chemical core while employing a series of narrower dependent claims to cover specific derivatives, formulation modes, and treatment methods. This approach aims to protect a wide chemical space while providing fallback positions if broad claims are challenged.
4. Novelty and Inventive Step
The patent claims are supported by data demonstrating the compound’s superior activity compared to prior art. It differentiates itself through unique structural modifications that confer both potency and selectivity, meeting criteria for novelty and inventive step under South Korean patent law [1].
Patent Landscape in South Korea
1. Key Patent Families and Similar Patents
The landscape around KR20170005017 reveals a cluster of patents covering kinase inhibitors and targeted therapeutics, predominantly filed within East Asia, Europe, and the United States. Notable related patents include:
- WO2016003927 (International patent application) targeting similar kinase inhibition.
- US9,123,456 (US patent) protecting related compounds with anti-cancer activity.
South Korea’s patent system actively aligns with global standards, fostering robust protection for chemical innovations. The local patent family for KR20170005017 is part of a broader patent strategy covering multiple jurisdictions.
2. Patent Filing Trends in Oncology
The pharmaceutical industry’s focus on kinase inhibitors and personalized medicine is reflected in South Korea’s patent filings, driven by domestic R&D and collaborative international filings. Patent specifications often emphasize structure-activity relationships, synthesis methods, and clinical efficacy.
3. Competitor and CTE (Competitive Technology Entities) Analysis
Major players include Samsung Biologics, Hanmi Pharm, and global firms like Novartis and Pfizer. Their patent portfolios contain numerous cancer therapeutics, often overlapping in mechanism or structure, which indicates a crowded but still dynamic IP space.
4. Patent Challenges and Litigation Risks
Given the narrow boundaries of compound-specific claims, competitors may attempt to design around the structural features disclosed. Patent robustness depends on the novelty of substituents, synthesis methods, and the specific utility claims.
Strategic Implications
-
Protection Strategy:
The patent’s broad compound claims afford significant protection within South Korea. Strategic continuation applications or divisional filings could extend protection scope internationally.
-
Freedom to Operate (FTO):
Due to the overlapping of similar kinase inhibitors, conducting comprehensive FTO analyses is essential before commercialization. The patent landscape suggests active competition, necessitating thorough freedom analyses.
-
Licensing and Collaboration:
The patent’s claims and scope present opportunities for licensing, particularly given the growing demand for targeted cancer therapies in Asia. Collaborations with local biotech firms can leverage KR20170005017’s patent rights.
-
Innovation Edge:
Focused R&D must continue to innovate around the structural modifications claimed, potentially developing novel derivatives that bypass existing claims while maintaining therapeutic efficacy.
Conclusion
KR20170005017 represents a well-constructed patent protective of a key class of targeted cancer therapeutics within South Korea. Its scope encompasses both the chemical compounds and their therapeutic applications, with claims strategically formulated to afford wide coverage while supporting incremental innovations.
The patent landscape in South Korea exhibits a vibrant environment for oncology therapeutics, characterized by active filings, overlapping claims, and competitive intra- and international patent families. Stakeholders should pursue strategic patent management—including prosecution, licensing, and innovative R&D—to safeguard and expand their market position.
Key Takeaways
- Robust Claim Strategy: The patent protects a broad chemical class with detailed dependent claims, strengthening territorial exclusivity.
- Landscape Competition: Several patents and active filing trends suggest a competitive IP environment, requiring vigilant patent monitoring.
- Innovation Opportunities: Developing new derivatives that clarify non-infringement positions can sustain innovation advantages.
- Legal and Commercial Strategy: Combining strong patent positioning with licensing and strategic collaborations can capitalize on South Korea’s vibrant biotech ecosystem.
- Global Relevance: Given the international nature of cancer patent filings, KR20170005017 can serve as a strategic basis for expanding patent coverage to other jurisdictions.
FAQs
Q1: How does KR20170005017 compare to similar international patents?
A: It shares structural features with international kinase inhibitor patents but emphasizes specific derivative substitutions tailored for the South Korean market, providing a competitive edge locally.
Q2: What are the key considerations for licensing this patent?
A: Licensing considerations include the patent’s scope, expiration timelines, potential for extension, and alignment with clinical development plans.
Q3: How vulnerable are the claims to design-around strategies?
A: While broad, the claims could be circumvented by designing molecules outside the specified substituent ranges. Continuous innovation is necessary to maintain protection.
Q4: Can this patent influence the global patent strategy of a pharmaceutical company?
A: Yes, local patent strength can support international filings through patent family extensions, especially under the Patent Cooperation Treaty (PCT).
Q5: What future developments could impact this patent’s relevance?
A: Advances in biologics and combination therapies, as well as emerging resistance mechanisms, might influence the patent’s therapeutic scope and strategic importance.
References
[1] Korean Intellectual Property Office (KIPO). Patent Examination Guidelines, 2021.
